Serotonergic agents

Details Serotonergic agents Serotonergic agents

2009-05-05

2010-10-19

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S364000

Reexamination Certificate

active

07816362

ABSTRACT:
Novel piperazine derivatives are provided having the formulawherein R1is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof, which are useful as 5-HT1Areceptor antagonists.

REFERENCES:
patent: 5532244 (1996-07-01), Wong et al.
patent: 5532250 (1996-07-01), Wong et al.
patent: 5532264 (1996-07-01), Wong et al.
patent: 5532268 (1996-07-01), Wong et al.
patent: 5538992 (1996-07-01), Wong et al.
patent: 5552429 (1996-09-01), Wong et al.
patent: 5710149 (1998-01-01), Cliffe et al.
patent: 5756532 (1998-05-01), Stack et al.
patent: 5776969 (1998-07-01), James
patent: 6127357 (2000-10-01), Cliffe et al.
patent: 6169105 (2001-01-01), Wong et al.
patent: 6172062 (2001-01-01), Clark et al.
patent: 6459007 (2002-10-01), Santi et al.
patent: 6469007 (2002-10-01), Childers et al.
patent: 6566112 (2003-05-01), Jones et al.
patent: 6586436 (2003-07-01), Childers et al.
patent: 6713626 (2004-03-01), Feigelson et al.
patent: 7026320 (2006-04-01), Childers et al.
patent: 7425558 (2008-09-01), Rizzo et al.
patent: 2003/0204087 (2003-10-01), Chan et al.
patent: 2004/0230056 (2004-11-01), Feigelson et al.
patent: 2005/0209245 (2005-09-01), Chan et al.
patent: 2005/0215561 (2005-09-01), Ghosh et al.
patent: 0 512 755 (1992-11-01), None
patent: 0 687 472 (1995-12-01), None
patent: 0 792 649 (1997-09-01), None
patent: WO-94/13643 (1994-06-01), None
patent: WO-94/13644 (1994-06-01), None
patent: WO-94/13661 (1994-06-01), None
patent: WO-94/13676 (1994-06-01), None
patent: WO-94/13677 (1994-06-01), None
patent: WO-95/33725 (1995-12-01), None
patent: WO-95/33743 (1995-12-01), None
patent: WO-97/03982 (1997-02-01), None
patent: WO-02/44142 (2002-06-01), None
patent: WO-03/078396 (2003-09-01), None
patent: WO-03/078417 (2003-09-01), None
patent: WO-2004/082686 (2004-09-01), None
Alexandre et al., 2006, “Early Life Blockage of 5-Hydroxytryptamine 1A Receptors Normalizes Sleep and Depression-Like Behavior in Adult Knock-Out Mice Lacking the Serotonin Transporter”, J. of Neuroscience, 26(20):5554-5564.
Artigas et al., 1996, “Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists”, Trends Neurosci. 19(9):378-383.
Azmitia, 2001, “Neuronal Instability: Implications for Rett's Syndrome”, Brain & Development, 23:S1-S10.
Balant, et al., 1995, “Metabolic Considerations in Prodrug Design”Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1, Wolff, ed., John Wiley & Sons, pp. 949-982.
Baldwin, 2004, “Sexual Dysfunction Associated with Antidepressant Drugs”, Expert Opin. Drug Saf., 3(5):457-470.
Berends et al., 2005, “A Review of the Neuroprotective Properties of the 5-HT1A Receptor Agonist Repinotan HCI (BAY x 3702) in Ischemic Stroke”, CNS Drug Reviews 11(4):379-402.
Beresford, et al., 2003, “Treatments for Stroke”, Expert Opin. Emerging Drugs, 8(1):103-122.
Blackburn, 2004, “Serotonergic Agents and Parkinson's Disease”, Drug Discovery Today: Therapeutic Strategies, 1(1):35-41.
Blanchard et al., 1997, “An Ethopharmacological Analysis of Selective Activation of 5-HT1A Receptors: The Mouse 5-HT1A Syndrome”, Pharmacology Biochem. and Behavior, 57(4):897-908.
Boast et al., 1999, “5HT Antagonists Attenuate MK801-Impaired Radial Arm Maze Performance in Rats”, Neurobiol. Learning Memory, 71:259-271.
Borg, et al., 2006, “Search for Correlations between Serotonin 5-HT1A, Receptor Expression and Cognitive Functions—a Strategy in Translational Psychopharmacology”, Psychopharmacology, 185:389-394.
Cao et al., 1998, “Tolerance to acute anxiolysis but no withdrawal anxiogenesis in mice treated chronically with 5-HT1A receptor antagonist, WAY 100635”, Neuroscience and Biobehavioral Reviews, 23:247-257.
Cao, 1997, “Influence of 5-HT1A Receptor Antagonism on Plus-Maze Behaviour in Mice”, Pharmacology Biochem. and Behavior, 58(2):593-603.
Carli et al., 1995, “(S)-WAY-100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine”, European J. Pharmacology, 283:133-139.
Carli et al., 1997, “WAY 100635, a 5-HT1AReceptor Antagonist, Prevents the Impairment of Spatial Learning Caused by Intrahippocampal Administration of Scopolamine or 7-Chloro-Kynurenic Acid”, Brain Res. 774:167-174.
Carli et al., 1999, “WAY 100635, a 5-HT1Areceptor antagonist, prevents the impairment of spatial learning caused by blocade of hippocampal NMDA receptors”, Neuropharmacol. 38:1165-1173.
Carli et al., 2000, “The 5-HT1AReceptor Agonist 8-OH-DPAT Reduces Rats' Accuracy of Attentional Performace and Enhances Impulsive Responding in a Five-Choice Serial Reaction Time Task: Role of Presynaptic 5-HT1AReceptors”, Psychopharmacol., 149:259-268.
Cheeta et al., 2001, “The dorsal raphe nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses”, Psychopharmacology, 155:78-85.
Childers, et al., 2005, “Synthesis and Biological Evaluation of Benzodioxanylpiperazine Derivatives as Potent Serotonin 5-HT1AAntagonists: The Discovery of Lecozotan”, J. Med. Chem., 48:3467-3470.
Collinson et al., 1997, “On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635”, Psychopharmacology (Berl). 132(1):35-43.
Cryan et al., 1999, “Comparative effects of serotonergic agonists with varying efficacy at the 5-HT1A receptor on core body temperature: modification by the selective 5-HT1A receptor antagonist WAY 100635”, J. Psychopharmacol., 13:278-283.
Dijk et al., 1995, “NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurons; evidence for modulation by a 5-HT1A antagonist”, British J. of Pharmacology, 115:1169-1174.
Dunlop, et al., 1998, “Characterization of 5-HT1AReceptor Functional Coupling in Cells Expressing the Human 5-HT1AReceptor as Assessed with the Cytosensor Microphysiometer”, J. Pharmacol. Tox. Methods, 40:47-55 (1998).
Duxon et al., 2000, “Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT1A receptor antagonist WAY100635”, British J. of Pharmaco., 130:1713-1719.
Ellingrod, et al., 1996, “Letters: Reassessment of Nefazodone”, Amer. Journal of Healt-System Pharmacy, 53(19):2339-2340, 2343.
Ellingrod, et al., 1996, “Nefazodone: A New Antidepressant”, Am. J. Health Syst. Pharm., 52:2799-2812.
European Examination Report for European Patent Application No. 06736178.2 mailed Jul. 29, 2008.
Fletcher et al., 1996, “Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist”, Behav. Brain Res., 73:337-353.
Gudelsky et al., 1986, “Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat”, Neuropharmacology, 25(12):1307-1313.
Harder et al., 2000, “The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys”, Neuropharmacol., 39:547-552.
Hjorth et al., 1997, “WAY 100653-induced Augmentation of the 5-HT-elevating Action of Citalopram: Relative Importance of the Dose of the 5-HT1A Auto)receptor Blocker Versus that of the 5-HT Reuptake Inhibitor”, Neuropharmacology, 36(4/5):461-465.
Hollander, et al., 1992, “Yohimbine Treatment of Sexual Side Effects Induced by Serotonin Reuptake Blockers”, J. Clin Psychiatry, 53(6):207-209.
Hughes et al., 1991, “Symptoms of Tobacco Withdrawal”, Arch. Gen. Psychiatry 48:52-59.
Hutson et al, 1988, “Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1A re

Affiliated with

Also associated with

Rating

Serotonergic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Serotonergic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serotonergic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4180407